Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Research Pipeline

This page shows the latest Research Pipeline news and features for those working in and with pharma, biotech and healthcare.

BenevolentAI claims AI first with new Cambridge facility

BenevolentAI claims AI first with new Cambridge facility

BenevolentAI claims AI first with new Cambridge facility. Says its new drug discovery and development base will cover the entire research process. ... The company has previously generated novel drug candidates to treat a range of complex and previously

Latest news

  • Artificial intelligence firm licenses Janssen candidates for development Artificial intelligence firm licenses Janssen candidates for development

    Janssen has licensed a number of pipeline candidates to a UK artificial intelligence company that wants to use technology to innovate the drug development process. ... The London-based firm said the agreement would enable it to accelerate its development

  • Top three therapeutic areas lead pharma’s pipeline Top three therapeutic areas lead pharma’s pipeline

    Top three therapeutic areas lead pharma’ s pipeline. Oncology dominates followed by CNS disorders and infectious diseases. ... Oncology, central nervous system (CNS) disorders and infectious diseases account for 68% of the overall pharmaceutical

  • Bayer confirms bid for Monsanto; will pharma suffer? Bayer confirms bid for Monsanto; will pharma suffer?

    Bayer's pharma business is in excellent health today, but the clock is ticking regarding rebuilding its pipeline," said Campbell in a research note. ... Will a stretched deal to acquire Monsanto impair its ability to supplement the pharma pipeline from

  • ViiV agrees $1.5bn deal to acquire BMS' HIV assets ViiV agrees $1.5bn deal to acquire BMS' HIV assets

    ViiV agrees $1.5bn deal to acquire BMS' HIV assets. Includes its entire development pipeline - from discovery to preclinical projects. ... The wide-ranging deal includes BMS' entire development pipeline - from discovery and preclinical research projects

  • AZ escapes censure over cancer tweet AZ escapes censure over cancer tweet

    This comes after an anonymous director of research, based in the US, complained about a tweet posted by AstraZeneca in December last year from the San Antonio Breast Cancer Symposium. ... AZ currently markets Faslodex (fulvestrant) for certain breast

More from news
Approximately 3 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    There are also a number of other drugs coming through the research pipelines. ... Pipeline growing. While Entresto and ivabradine promise to make a significant impact in HF, there are also a number of other investigational drugs coming through the

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    Research pipeline. Research at Eisai is focused on three key areas: neuroscience, oncology and vascular/immunological diseases. ... Commercial expansion. But it's not just in research spending that Eisai is bucking industry trends.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia